托法替布治疗类风湿关节炎继发干燥综合征临床疗效  

Clinical Efficacy of Tofacitinib in the Treatment of Rheumatoid Arthritis Secondary to Sjogrensyndrome

作　　者：鲍星兰 袁红建[1] BAO Xinglan;YUAN Hongjian(Department of Rheumatology and Immunology,Taizhou Second People's Hospital,Taizhou,Jiangsu Province,225500 China)

机构地区：[1]泰州市第二人民医院风湿免疫科,江苏泰州225500

出　　处：《系统医学》2024年第5期61-63,83,共4页Systems Medicine

摘　　要：目的探讨分析托法替布对类风湿关节炎继发干燥综合征患者的治疗效果。方法选取2021年5月—2023年2月泰州市第二人民医院收治的72例类风湿关节炎继发干燥综合征患者为研究对象,按照信封随机法分为两组,参照组(36例)接受单纯甲氨蝶呤治疗,研究组(36例)联合托法替布治疗,比较两组的治疗效果。结果治疗后,研究组肿胀关节个数(3.8±1.0)个、压痛关节个数(6.3±2.0)个均少于参照组的(4.7±1.6)、(8.6±2.1)个,差异有统计学意义(t=2.862、4.759,P均<0.05);研究组类风湿关节炎治疗有效率为97.22%,高于参照组的77.78%,差异有统计学意义(χ^(2)=6.222,P=0.013);研究组干燥综合征治疗有效率为(97.22%)高于参照组(80.56%),差异有统计学意义(χ^(2)=5.062,P=0.024)。结论对类风湿关节炎继发干燥综合征患者采用托法替布进行治疗,能够取得极为确切的疗效,缓解患者的病情,减轻患者的临床不适症状,改善其生活质量。同时,能够调节患者的机体状态,切实减轻患者的关节压痛程度,使患者可以恢复正常的工作与生活。Objective To explore and analyze the therapeutic effect of tofacitinib in patients with rheumatoid arthritis secondary to sjogrensyndrome.Methods 72 patients with rheumatoid arthritis secondary sjogren's syndrome admitted to Taizhou Second People's Hospital from May 2021 to February 2023 were selected as the study subjects,and they were divided into two groups according to envelope random method.The reference group(36 cases)received sole methotrexate treatment,and the study group(36 cases)received combined tofacatib treatment,and the therapeutic ef⁃fects of the two groups were compared.Results After treatment,the number of swollen joints(3.8±1.0)and tender joints(6.3±2.0)in the study group was lower than that in the reference group(4.7±1.6)and(8.6±2.1),and the differ⁃ences were statistically significant(t=2.862,4.759,both P<0.05).The effective rate of rheumatoid arthritis treatment in the study group was 97.22%,higher than that in the reference group(77.78%),and the difference was statistically significant(χ^(2)=6.222,P=0.013).The effective rate of sjogren's syndrome treatment in the study group was 97.22%,higher than that in the reference group(80.56%),and the difference was statistically significant(χ^(2)=5.062,P=0.024).Conclusion The use of tofacatib in the treatment of patients with rheumatoid arthritis secondary sjogren's syndrome can achieve very precise curative effect,alleviate the patient's condition,reduce the clinical discomfort symptoms of patients,and improve their quality of life.At the same time,it can adjust the body state of the patient,effectively reduce the degree of joint tenderness of the patient,so that the patient can return to normal work and life.

关 键 词：类风湿关节炎 干燥综合征 托法替布 甲氨蝶呤 治疗效果 

分 类 号：R593.2[医药卫生—内科学]